Navigation Links
PrimeVax Immuno-Oncology to Present at Biocom Global Life Science Partnering Conference
Date:2/22/2017

SAN DIEGO, Feb. 22, 2017 /PRNewswire/ -- PrimeVax Immuno-Oncology, Inc. announced today its CEO, Tony Chen, will be presenting at the Annual Biocom Global Life Science Partnering Conference.  The presentation will take place on March 2, at 11:15 AM, at the Torrey Pines Lodge, in San Diego. 

"We are thankful to the organizers at Biocom who have chosen our company, amongst numerous others, to present at this international symposium of biotechnology companies, investors, and clinical researchers," said Mr. Chen. "In contrast to conferences in previous years, there is an increase in the number of cancer immunotherapy companies presenting. This trend reflects the excitement we observe in the industry where new methods are being tried to fight cancer."

PrimeVax takes a unique approach to treating cancer by combining virus-induced immune stimulation and dendritic cell therapy.  A description of the PrimeVax approach was recently published in the peer-reviewed literature by the company management1.

"With the clinical implementation of various immunotherapeutic strategies, it is becoming more and more apparent that we need to activate multiple arms of the immune system at the same time," said Santosh Kesari, MD, PhD, Scientific Co-Founder of PrimeVax and Chair of Neurosciences and Neurotherapeutics at the John Wayne Cancer Institute and Pacific Neuroscience Institute. "We are very excited about the progress that Mr. Chen has made in advancing this technology, and I look forward to helping patients suffering from deadly cancers such as melanoma and glioblastoma."

About Us

PrimeVax Immuno-Oncology, Inc. is focused on development of personalized immunotherapy by leveraging its PV-001 platform.  The platform enables PrimeVax to develop a 1 time 1 week cancer treatment schedule for many cancer types agnostic of tumor mutation characteristics. PV-001 leverages the body's innate and adaptive immune responses simultaneously to trigger activation of T cells, NK cells, and other immunotherapeutic effects. The Company was founded in 2015 and will engage in human clinical trials in 2017. Initial indications to be targeted are metastatic melanoma, triple negative breast cancer, and glioblastoma.

Contact:   
PrimeVax Immuno-Oncology, Inc.    
Tony Chen  
CEO  
Tony.Chen@PrimeVax.com  
PrimeVax Immuno-Oncology

1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307212/pdf/12967_2014_Article_349.pdf

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/primevax-immuno-oncology-to-present-at-biocom-global-life-science-partnering-conference-300411608.html


'/>"/>
SOURCE PrimeVax Immuno-Oncology, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February
2. Applied BioMath, LLC presents work in immuno-oncology and antibody drug-conjugates at Keystone Symposium
3. Genedata Partners with Crescendo Biologics on Next-generation Immuno-oncology and ADC Programs
4. Eutilex Completes $18 Million Series A Financing to Advance Immuno-Oncology Programs
5. Immuno-Oncology: A 360° View in NYC this February
6. F-star Selects Genedata Biologics for Immuno-Oncology Therapeutics Discovery
7. PharmaVentures Advises 3Legs Resources on its Acquisition of the Immuno-Oncology Company SalvaRx Who Announced its Admission for Trading on AIM Today
8. HUYA Bioscience International Acquires Exclusive Rights to Immuno-Oncology Products from Fudan University
9. Immune Pharmaceuticals Announces 2016 Immuno-Oncology Plan
10. F-star Enters Into Collaborative Discovery & Development Agreement With AbbVie for Bispecific Antibodies in Immuno-oncology
11. Infinity to Provide Update on Duvelisib and Immuno-Oncology Development Candidate IPI-549 During 2015 Research and Development Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2017)... ... September 17, 2017 , ... ... Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New Drug ... Middle East Respiratory Syndrome coronavirus (MERS-CoV). The study in Korea represents the second ...
(Date:9/14/2017)... , ... September 14, 2017 ... ... the launch of its CliniControl™ (CC) product portfolio, clinically-relevant starting and ancillary ... translation of human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio ...
(Date:9/14/2017)... , ... September 14, 2017 , ... AIM Global, the ... Tracking Systems Inc. has won the 2017 Case Study Competition for AIDC. The ... provide benefits that decrease risk” and push the adoption of automated data collection systems ...
(Date:9/12/2017)... ... 12, 2017 , ... PhysIQ, a Chicago-based company that provides ... monitoring and clinical trial support, earned DPharm Idol 2017 honors at the 7th ... Launched in 2005, PhysIQ leverages artificial intelligence (AI) to empower digital health. The ...
Breaking Biology Technology:
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 /PRNewswire/ ... leader in dairy research, today announced a new collaboration ... reduce the chances that the global milk supply is ... dairy project, Cornell University has become the newest academic ... Supply Chain, a food safety initiative that includes IBM ...
(Date:5/16/2017)... -- Veratad Technologies, LLC ( www.veratad.com ), an innovative and ... solutions, announced today they will participate as a sponsor ... May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions of ... digital world, defining identity is critical to nearly every ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
Breaking Biology News(10 mins):